However, in a small percentage of the EGFR-treated population (3–15%), the patient’s tumor has a histological transformation from non-small cell lung cancer (NSCLC), adenocarcinoma in particular, to neuroendocrine differentiated histology, specifically small cell lung cancer (SCLC) [3,4]. This evidence concerns the gene EGFR and neoplasm.